Search Results - kazusa+ishii

3 Results Sort By:
Tiered Screening of Therapeutic TCRs for Identification of Autoimmune Cross-Reactivity
Summary: The National Cancer Institute seeks research co-development partners and/or licensees for a standardized method of detecting T-cell receptor (TCR) cross-reactivity as a means of proving safety and efficacy in preclinical evaluations ahead of clinical trials. Description of Technology: TCR-based therapies targeting cancer-associated antigens...
Published: 12/18/2024   |   Inventor(s): Kazusa Ishii, Christian Hinrichs, John Davies
Keywords(s):  
Category(s): TherapeuticArea > Immunology, TherapeuticArea > Oncology, Application > Research Materials, Application > Therapeutics, Collaboration Sought > Collaboration, Collaboration Sought > Licensing
T-cell Receptors Targeting CD20-Positive Lymphomas and Leukemias
Abstract: CD20 is a protein expressed by wide ranges of lymphoid malignancies originating from B cells but not by indispensable normal tissues, making it an attractive target for therapies such as T-cell receptor (TCR) therapy. Current anti-CD20 therapeutics face a number of limitations. The most important limitation to current anti-CD20 therapies include...
Published: 8/14/2024   |   Inventor(s): Kazusa Ishii, Christian Hinrichs
Keywords(s): Acute Lymphoblastic Leukemia, ALL, CD20, Chronic lymphocytic leukemia, CLL, Hinrichs, Ishii, NHL, Non-Hodgkin’s Lymphoma, Resistant B-lymphoid malignancies, T-Cell Receptor, TCR
Category(s): Collaboration Sought > Licensing, TherapeuticArea > Oncology, Application > Therapeutics
T Cell Receptor Targeting CD22 for the Treatment of Lymphomas and Leukemias
Abstract: CD22 is a protein expressed by normal B cells and B-lymphoid malignancies. Its limited tissue expression pattern makes it a safe antigen for targeted therapies, such as T-cell Receptor (TCR)-T cell therapy. CD22-targeting therapies already on the market, mainly antibody-immunotoxin conjugates and chimeric antigen receptors (CAR)-T cells, have...
Published: 12/17/2024   |   Inventor(s): Kazusa Ishii, Christian Hinrichs
Keywords(s): Acute Lymphoblastic Leukemia, ALL, B cells, CD22, Cellular Immunotherapy, Chronic lymphocytic leukemia, CLL, Hinrichs, Ishii, NHL, Non-Hodgkin’s Lymphoma, Relapsed / refractory B-Lymphoid Malignancies, T-Cell Receptor, TCR
Category(s): Application > Therapeutics, Collaboration Sought > Licensing, Collaboration Sought > Collaboration, TherapeuticArea > Oncology